Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Safusidenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvation Bio Acquires Japan Rights to Safusidenib from Daiichi
    Nuvation Bio Acquires Japan Rights to Safusidenib from Daiichi

    01 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvation-bio-announces-acquisition-of-japan-rights-to-safusidenib-from-daiichi-sankyo-302730492.html

    PR NEWSWIRE
    01 Apr 2026
    Share Share
    Nuvation Bio Reveals 2025 Financials And Business Update
    Nuvation Bio Reveals 2025 Financials And Business Update

    02 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvation-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-302701317.html

    PR NEWSWIRE
    02 Mar 2026
    Share Share
    Nuvation Bio Launches Global Phase 3 Trial For Safusidenib
    Nuvation Bio Launches Global Phase 3 Trial For Safusidenib

    09 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260204350848/en/Nuvation-Bio-Announces-Pivotal-Global-Phase-3-SIGMA-Trial-G203-for-Safusidenib-in-IDH1-Mutant-Glioma

    BUSINESSWIRE
    09 Feb 2026
    Share Share
    Nuvation Bio Publishes Positive Phase 2 Results For Safusidenib
    Nuvation Bio Publishes Positive Phase 2 Results For Safusidenib

    03 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251203703470/en/Nuvation-Bio-Announces-Publication-of-Positive-Phase-2-Study-Results-for-Safusidenib-for-the-Treatment-of-Grade-2-IDH1-Mutant-Glioma-in-Neuro-Oncology

    BUSINESSWIRE
    03 Dec 2025
    Share Share
    Nuvation Enrolls 1st Patient in Randomized Study of Safusidenib
    Nuvation Enrolls 1st Patient in Randomized Study of Safusidenib

    04 Nov 2025

    // PRESS RELEASE

    https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma/default.aspx

    PRESS RELEASE
    04 Nov 2025
    Share Share
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023640173/en/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.